Novel immunotherapy successful in reducing tumor size in high-risk neuroblastoma patients

Written by Courtney Johnson

A new, ongoing study, being carried out at St Jude Children’s Research Hospital (TN, USA) has exhibited success in shrinking neuroblastoma tumors in young high-risk patients. Within the cohorts of children and teenagers who participated in the study, almost 40% completed treatment exhibiting no signs of disease. The preliminary findings were reported recently at the American Society of Clinical Oncology Annual Meeting (3–7 June, IL, USA). Neuroblastoma is diagnosed in approximately 700 individuals per year in the USA, with the majority of diagnoses being made for children 5 years old or younger. Roughly 10% of these cases are identified as...

To view the full article, please register now for access

It's completely free